Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for 89BIO (ETNB : NSDQ)

• Company Description    89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis. 89bio Inc. is headquartered in San Francisco. Number of Employees: 93

• Price / Volume Information    Yesterday's Closing Price: $8.07 Daily Weekly Monthly 20 Day Moving Average: 1,340,342 shares Shares Outstanding: 148.31 (millions) Market Capitalization: $1,196.85 (millions) Beta: 1.27 52 Week High: $11.84 52 Week Low: $4.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.32% -12.88% 12 Week -19.30% -26.70% Year To Date 3.20% -1.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 655 MONTGOMERY STREET SUITE 1500 - SAN FRANCISCO,CA 94111 USA ph: 415-432-9270 fax: - investors@89bio.com http://www.89bio.com

• General Corporate Information    Officers Rohan Palekar - Chief Executive Officer and Director Ryan Martins - Chief Financial Officer Steven Altschuler - Director Edward Morrow Atkinson - Director Martin Babler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 282559103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 148.31 Most Recent Split Date: (:1) Beta: 1.27 Market Capitalization: $1,196.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.24 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 15.47% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.26 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -47.92% vs. Previous Quarter: -44.90% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -94.48 03/31/25 - -81.44 12/31/24 - -81.38 ROA 06/30/25 - -80.92 03/31/25 - -70.17 12/31/24 - -70.04 Current Ratio 06/30/25 - 15.19 03/31/25 - 18.03 12/31/24 - 13.19 Quick Ratio 06/30/25 - 15.19 03/31/25 - 18.03 12/31/24 - 13.19 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 3.57 03/31/25 - 4.15 12/31/24 - 3.34 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.07 03/31/25 - 0.06 12/31/24 - 0.09 Debt-to-Capital 06/30/25 - 6.48 03/31/25 - 5.60 12/31/24 - 8.19

Powered by Zacks Investment Research ©